Hematology-Oncology and Stem Cell Transplantation Unit, National Cancer Institute, Fondazione G. Pascale IRCCS, Naples, Italy.
Eur Rev Med Pharmacol Sci. 2012 Jun;16(6):781-8.
Promise in the future, a disease could be ranked into genetic categories, allowing bespoke tailoring of medicine to maximize therapeutic effects and to reduce the potential for adverse drug response. This new feature requires for health professionals to have competencies not only for the basic skills of their discipline, but also for the understanding on why, when, and how that knowledge should be applied to improve personalized therapies for their patients. Current opinion on basic competences of health professions includes knowledge and skills on two fundamental features: (1) genetics of disease, to allow the understanding and the identification of diseases associated to genetic variations, and to facilitate the development of new genomic tests; and (2) ethical, social and economical implications that are fundamental to identify those factors that might contribute to a successful integration of pharmacogenomics into international health and public policy.
Briefly, we described (1) current knowledge on genetic variations that interact with therapies and the need to detect them; (2) the most common available methods for detecting mutations; and (3) ethical, social and economic issues related to pharmacogenetic testing and recording of genetic information (e.g., critical evaluation of the development of new tests, privacy, the current absence of public reimbursement, etc).
These could be useful recommendations for academic institutions and educational programs to prepare health professionals with the necessary abilities for their future practice.
未来,一种疾病可以被归类为遗传类别,从而可以定制药物,以最大限度地提高治疗效果,并降低药物不良反应的可能性。这项新功能要求卫生专业人员不仅具备其学科基本技能的能力,还需要了解为什么、何时以及如何将这些知识应用于改善患者的个性化治疗。目前对卫生专业人员基本能力的看法包括对两个基本特征的知识和技能:(1)疾病的遗传学,以允许理解和识别与遗传变异相关的疾病,并促进新的基因组测试的发展;(2)伦理、社会和经济方面的影响,这些是确定可能有助于将药物基因组学成功整合到国际卫生和公共政策中的因素的基础。
简要描述(1)与治疗方法相互作用的遗传变异的当前知识,以及检测这些变异的必要性;(2)检测突变的最常见方法;以及(3)与药物遗传学检测和遗传信息记录相关的伦理、社会和经济问题(例如,对新检测方法的开发、隐私、当前缺乏公共报销等进行批判性评估)。
这些建议对学术机构和教育项目来说可能是有用的,可以为卫生专业人员未来的实践做好必要能力的准备。